PREVACID (lansoprazole) Delayed-Release Capsules PREVACID SoluTab (lansoprazole) Delayed-Release Orally Disintegrating Tablets For oral administration
ثبت نشده
چکیده
-----------------------------DRUG INTERACTIONS-------------------------- • Atazanavir: Do not co-administer with atazanavir. (7.1) • Drugs with pH-Dependent Absorption: May interfere with the absorption of drugs where gastric pH is important for bioavailability. (7.1) • Warfarin: Concomitant warfarin use may require monitoring for increases in INR and prothrombin time. (7.2) • Tacrolimus: Concomitant tacrolimus use may increase tacrolimus whole blood concentrations. (7.3) • Theophylline: Titration of theophylline dosage may be required when concomitant PREVACID use is started or stopped. (7.4) • Methotrexate: PREVACID may increase serum levels of methotrexate. (7.6)
منابع مشابه
PREVACID (lansoprazole) Delayed-Release Capsules PREVACID (lansoprazole) For Delayed-Release Oral Suspension PREVACID SoluTab (lansoprazole) Delayed-Release Orally Disintegrating Tablets For oral administration
Dual Therapy: PREVACID Amoxicillin 30 mg 1 gram Three times daily for 14 days Benign Gastric Ulcer Short-Term Treatment (1.4) 30 mg Once daily up to 8 wks NSAID-associated Gastric Ulcer (1.6) Healing Risk Reduction 30 mg 15 mg Once daily for 8 wks Once daily up to 12 wks GERD (1.7) Short-Term Treatment of Symptomatic GERD 15 mg Once daily up to 8 wks Short-Term Treatment of EE 30 mg Once daily ...
متن کاملLansoprazole is an antituberculous prodrug targeting cytochrome bc1
Better antibiotics capable of killing multi-drug-resistant Mycobacterium tuberculosis are urgently needed. Despite extensive drug discovery efforts, only a few promising candidates are on the horizon and alternative screening protocols are required. Here, by testing a panel of FDA-approved drugs in a host cell-based assay, we show that the blockbuster drug lansoprazole (Prevacid), a gastric pro...
متن کاملNew Drugs Drug News
124 P&T® • March 2009 • Vol. 34 No. 3 NEW DRUGS Dexlansoprazole (Kapidex) For Esophageal Disease The FDA has approved dexlansoprazole delayed-released capsules (Kapidex, Takeda Pharmaceuticals) to treat heartburn associated with symptomatic non erosive gastroesophageal reflux disease (GERD), the healing of erosive esophagitis, and the maintenance of healed erosive esophagitis. Acid reflux disea...
متن کاملIngestibility and Formulation Quality of Lansoprazole Orally Disintegrating Tablets
Objectives. We evaluated the ingestibility and formulation quality of one branded (formulation A) and five generic (formulations B, C, D, E, and F) lansoprazole orally disintegrating (OD) tablets. Methods. Ingestibility, including the oral disintegrating time, taste, mouth feeling, and palatability, was examined by sensory testing in healthy subjects. Formulation qualities, including salivary s...
متن کاملFormulation study for lansoprazole fast-disintegrating tablet. I. Effect of compression on dissolution behavior.
Lansoprazole fast-disintegrating tablet (LFDT) is a new patient-friendly formulation of lansoprazole. Since lansoprazole is an antiulcer agent and is unstable under acidic conditions, we have developed LFDT as an orally disintegrating tablet containing enteric-coated microgranules. The effect of compression on dissolution behavior was investigated, as compression affected cleavage and crushing ...
متن کامل